First National Trust Co Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

First National Trust Co cut its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,469 shares of the company’s stock after selling 2,624 shares during the quarter. Johnson & Johnson comprises about 0.9% of First National Trust Co’s investment portfolio, making the stock its 25th biggest position. First National Trust Co’s holdings in Johnson & Johnson were worth $24,385,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Meridian Financial Partners LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $1,626,000. Lmcg Investments LLC grew its holdings in Johnson & Johnson by 32.7% during the 3rd quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock valued at $14,125,000 after purchasing an additional 21,471 shares in the last quarter. Cooper Haims Advisors LLC lifted its holdings in Johnson & Johnson by 6.4% in the 1st quarter. Cooper Haims Advisors LLC now owns 3,358 shares of the company’s stock worth $531,000 after buying an additional 201 shares in the last quarter. Trajan Wealth LLC boosted its position in Johnson & Johnson by 11.3% in the 3rd quarter. Trajan Wealth LLC now owns 32,992 shares of the company’s stock valued at $5,347,000 after buying an additional 3,341 shares during the last quarter. Finally, Entropy Technologies LP grew its stake in shares of Johnson & Johnson by 127.5% during the first quarter. Entropy Technologies LP now owns 37,592 shares of the company’s stock valued at $5,947,000 after acquiring an additional 21,071 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $152.64 on Wednesday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The stock has a market capitalization of $367.50 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 2.76 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock’s fifty day moving average is $162.39 and its two-hundred day moving average is $155.97.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period in the previous year, the business posted $2.66 EPS. Johnson & Johnson’s revenue was up 5.2% on a year-over-year basis. On average, research analysts predict that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.25%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.

Analysts Set New Price Targets

A number of research analysts recently commented on JNJ shares. Wells Fargo & Company increased their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Guggenheim raised their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Royal Bank of Canada boosted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $175.00.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.